Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06870253 · ClinicalTrials.gov registry record
Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases
A clinical trial of Bladder Cancer and Urothelial Carcinoma Bladder, sponsored by Pangea Laboratory.
- Active
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT06870253: Active study of Bladder Cancer and Urothelial Carcinoma Bladder, sponsored by Pangea Laboratory.
NCT06870253 is a study of Bladder Cancer and Urothelial Carcinoma Bladder that is active but no longer recruiting, run by Pangea Laboratory. The registered enrollment target is 80 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06870253, a study of Bladder Cancer and Urothelial Carcinoma Bladder, is active but no longer recruiting, sponsored by Pangea Laboratory.
- ACTIVE NOT RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn about the performance of the Bladder CARE™ Assay in patients suspected of having bladder cancer with atypical cytology or equivocal cystoscopy results. The main question it aims to answer is: • Does the Bladder CARE™ Assay detect bladder cancer in patients who have inconclusive cytology or cystoscopy results? Participants will provide one voided urine specimen on the day of, and prior to, the routine, scheduled standard of care initial or repeat cystoscopy procedure. A medical records review will occur at two follow-up timepoints, (6 months and 12 months after the urine specimen collection), to document oncology-urinary-related clinical outcomes.
Primary Outcome
Assess the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), of the Bladder CARE™ Assay to the gold standard diagnostic methods for detecting bladder cancer in patients with atypical cytology or equivocal cystoscopy results.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-06-03 |
| Est. Completion | 2027-03 |
What the registry record for NCT06870253 still lists
NCT06870253 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06870253 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06870253 about?
NCT06870253 is a clinical study titled "Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases". The goal of this observational study is to learn about the performance of the Bladder CARE™ Assay in patients suspected of having bladder cancer with atypical cytology or equivocal cystoscopy results. The main question it aims to answer is: • Does the Bladder CARE™ Assay detect bladder cancer in pa...
What is the current status of trial NCT06870253?
This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2025-06-03. Estimated completion is 2027-03.
What conditions does trial NCT06870253 study?
This clinical trial studies the following conditions: Bladder Cancer, Urothelial Carcinoma Bladder.
Who is sponsoring clinical trial NCT06870253?
This trial is sponsored by Pangea Laboratory, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06870253 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06870253's enrollment target sits among peer trials
80 93rd of 175 higher than 81 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI